MedPath

Caplin Steriles Gains FDA Approval for Generic Difluprednate Eye Drops

• Caplin Steriles has received FDA approval for its generic version of difluprednate ophthalmic emulsion, 0.05%, a therapeutic equivalent to DUREZOL. • The approval allows Caplin Steriles to market a more affordable alternative for treating inflammation and pain associated with ocular surgery. • This generic medication mirrors Sandoz Inc.'s DUREZOL, offering similar efficacy and safety profiles for patients requiring corticosteroid treatment in the eye. • The FDA's decision underscores Caplin Steriles' commitment to providing accessible and cost-effective pharmaceutical options in the ophthalmology space.

Caplin Steriles has secured FDA approval for its generic difluprednate ophthalmic emulsion, 0.05%, offering a cost-effective alternative to Sandoz Inc.'s DUREZOL for treating ocular inflammation and pain. This approval marks a significant step for Caplin Steriles in expanding its portfolio of accessible pharmaceutical products.
The generic difluprednate eye drops are indicated for the treatment of inflammation and pain associated with ocular surgery. Difluprednate is a corticosteroid that helps reduce swelling, redness, and pain in the eye following surgical procedures. By providing a generic option, Caplin Steriles aims to lower the financial burden on patients requiring such treatment.
The approved product is a therapeutic equivalent to DUREZOL, meaning it has the same active ingredient, strength, dosage form, and route of administration, and is bioequivalent. This ensures that patients receive the same clinical benefit as with the brand-name drug. The FDA's approval is based on a review of data demonstrating that the generic version meets the agency's rigorous standards for safety and efficacy.
Caplin Steriles' generic difluprednate eye drops will provide an additional treatment option for healthcare professionals managing patients' post-operative ocular health. The company anticipates a positive reception from both physicians and patients seeking affordable yet effective solutions for managing eye inflammation and pain.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Zhaoke Ophthalmology's TAB014 Shows Positive Phase 3 Results; Valo Health Shelves OPL-0401

Zhaoke Ophthalmology's TAB014 met primary and key secondary endpoints in a Phase 3 trial for wet age-related macular degeneration (AMD).
Caplin Steriles received FDA approval for its generic difluprednate ophthalmic emulsion, used to treat inflammation and pain after ocular surgery.

Safilens Secures FDA Approval for Deseyne Daily Contact Lenses

Safilens has received FDA approval to market its fusion 1day daily contact lenses, branded as Deseyne, in the United States.
The approval marks a significant milestone for Safilens, making it the first Italian company in the sector to register its material, Vifilcon C, in the U.S.

Lupin Gains FDA Approval for Generic Adderall XR for ADHD Treatment

Lupin has received FDA approval for its generic version of Adderall XR, an extended-release capsule used to treat ADHD in adults and children.
The approved Abbreviated New Drug Application (ANDA) includes multiple dosage strengths, ranging from 5 mg to 30 mg.

Grifols' VISTASEAL Receives FDA Approval for Pediatric Surgical Bleeding

Grifols' fibrin sealant (FS), VISTASEAL, gains FDA approval for controlling surgical bleeding in pediatric patients, expanding its availability in the U.S.
The approval is based on a Phase 3b study demonstrating over 95% efficacy in achieving hemostasis within four minutes in pediatric patients.

FDA Approves VISTASEAL Fibrin Sealant for Pediatric Surgical Bleeding

The FDA has approved VISTASEAL, a fibrin sealant from Grifols, for controlling surgical bleeding in pediatric patients.
VISTASEAL combines fibrinogen and thrombin proteins to promote hemostasis and tissue sealing during surgery, reducing blood loss.

Grifols' Fibrin Sealant Gains FDA Approval for Pediatric Surgical Bleeding

Grifols' fibrin sealant (FS) has been approved by the FDA for use in pediatric patients undergoing surgery to control bleeding, expanding its availability in the U.S.
The approval is based on a Phase 3b study demonstrating the safety and efficacy of Grifols FS in achieving hemostasis within four minutes in pediatric surgical patients.

Grifols' Fibrin Sealant VISTASEAL™ Receives FDA Approval for Pediatric Surgical Bleeding

Grifols' VISTASEAL™ fibrin sealant secures FDA approval for managing surgical bleeding in pediatric patients in the U.S.
A Phase 3b trial demonstrated over 95% efficacy in achieving hemostasis within four minutes of VISTASEAL™ application.

Aurobindo Pharma Gains US FDA Approval for Cephalexin Antibiotic Tablets

Aurobindo Pharma has received US FDA approval to manufacture and market Cephalexin Tablets USP in 250 mg and 500 mg dosages, used to treat various infections.
The approved tablets are bioequivalent and therapeutically equivalent to Keflet tablets, ensuring similar efficacy and safety profiles for patients.

FDA Approves Nymalize in Prefilled ENFit Syringes for Subarachnoid Hemorrhage

The FDA has approved Nymalize (nimodipine) oral solution in prefilled ENFit syringes, offering a potentially more secure drug administration method.
Nymalize is indicated for improving neurological outcomes by reducing ischemic deficits in adults with subarachnoid hemorrhage from ruptured intracranial aneurysms.

Cresilon Receives FDA Clearance for TRAUMAGEL

Cresilon Inc. has received FDA 510(k) clearance for TRAUMAGEL, a plant-based hemostatic gel designed to control moderate to severe bleeding in seconds. This innovative product aims to save lives by quickly stopping life-threatening bleeding at the point of care.

Reference News

[1]
Caplin Steriles Receives FDA Approval For Generic Difluprednate Eye Drops - NDTV Profit
ndtvprofit.com · Dec 16, 2024

Caplin Steriles receives FDA approval for generic difluprednate eye drops, equivalent to Sandoz Inc's DUREZOL.

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy